Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2024 | $88.00 → $84.00 | Buy | Needham |
| 8/2/2024 | $90.00 | Buy | Rodman & Renshaw |
| 6/28/2024 | Neutral | Guggenheim | |
| 2/15/2024 | Peer Perform | Wolfe Research | |
| 12/11/2023 | $30.00 | Market Perform → Underperform | TD Cowen |
| 10/17/2023 | Overweight → Neutral | Cantor Fitzgerald | |
| 9/27/2023 | $82.00 | Buy | Mizuho |
| 8/17/2023 | Neutral → Buy | Citigroup |
4 - CRISPR Therapeutics AG (0001674416) (Issuer)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)
ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:00 p.m. GMT. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the pre
ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics, will present at the Guggenheim Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024, at 2:00 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days follo
-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treatment centers (ATCs) activated globally for CASGEVY and approximately 40 patients have had cells collected across all regions as of mid-October- -Two clinical trials are ongoing for next generation CAR T product candidate, CTX112™ targeting CD19, in B-cell malignancies and systemic lupus erythematosus- -Two clinical trials are ongoing for next generation CAR T product candidate, CTX131™, targeting CD70, in solid tumors and hematological malignancies- -Company plans to provide an update on t
Needham reiterated coverage of CRISPR Therapeutics with a rating of Buy and set a new price target of $84.00 from $88.00 previously
Rodman & Renshaw initiated coverage of CRISPR Therapeutics with a rating of Buy and set a new price target of $90.00
Guggenheim resumed coverage of CRISPR Therapeutics with a rating of Neutral
SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)
SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)
SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)
10-Q - CRISPR Therapeutics AG (0001674416) (Filer)
8-K - CRISPR Therapeutics AG (0001674416) (Filer)
S-3ASR - CRISPR Therapeutics AG (0001674416) (Filer)
-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, effective May 28, 2024. Dr. Patel is an experienced drug developer who has worked across a wide range of disease areas, including his most recent leadership role as the Global Development Therapeutic Area Head of Immunology and Inflammation at Sanofi. In addition, the Company al
ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the hiring and appointment of Raju Prasad, Ph.D., as Chief Financial Officer, effective March 14, 2023. He joins CRISPR Therapeutics from William Blair & Company, where he served as a Partner and Senior Equity Research Analyst covering cell therapy, gene therapy, and gene editing companies. Dr. Prasad succeeds Brendan Smith, who is leaving the Company to pursue external opportunities. "I'm excited to welcome Raju to our leadership team," said Samarth Kulkarni, Ph.D., Chief Exec
ZUG, Switzerland and BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Alex Harding, M.D., M.B.A., as Senior Vice President and Head of Business Development, effective January 5, 2023. Dr. Harding brings extensive leadership experience in biopharma business development and corporate strategy and joins CRISPR Therapeutics to lead the Company's business development operations. "Alex's broad-based experience in strategic business development, venture formation and platform expansion will be critical in driving the next phase
-58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis- -Durable responses in LBCL achieved with six-month CR rate of 21% and longest response on-going at over 18 months after initial infusion- -Response rates and durability are similar to approved autologous CD19 CAR-T therapies on an ITT basis- -Positively differentiated safety profile; no Grade 3 or higher cytokine release syndrome (CRS) and low rates of infection and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)- -Expanding CARBON into a potentially registrational trial in 1Q 20
-Management to host conference call and webcast on October 12th at 4:30 p.m. ET- ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that management will host a virtual event on October 12, 2021 at 4:30 p.m. ET to highlight clinical data from its ongoing Phase 1 CARBON trial assessing the safety and efficacy of CTX110, its wholly-owned allogeneic chimeric antigen receptor T cell (CAR-T) investigational therapy targeting CD19, for the treatment of relapsed or refractory B-cell malignancies. Conference Call and Web
In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company’s flagship fund, ARK Innovation ETF (NYSE:ARKK), despite its recent underperformance. What Happened: Wood, in her letter, acknowledged that ARKK’s performance has been impacted by the shift in focus from the “Magnificent Six” to multiomics stocks, which have been adversely affected by the prospect of prolonged high interest rates. Despite this, ARKK’s valuation has dropped to a level that Wood believes is indicative of “deep value territory” over a five-year investment horizon. Wood pointed out that ARKK’s valuation, as of June, was 25.5x, the lowest it has been since Febru
Guggenheim analyst Debjit Chattopadhyay assumes CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral rating.
Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $88 price target.